Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | TLR4 | O00206 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25061 | 1.00 | MAPK1 (0.47) | MAPK1MCL1KDM4EHSD17B10CYP1A2 | |
| SCHEMBL31276435 | 1.00 | MAPK1 (0.47) | MAPK1MCL1KDM4EHSD17B10CYP1A2 | |
| SCHEMBL31198171 | 0.98 | MAPK1 (0.46) | MAPK1MCL1KDM4EHSD17B10CYP1A2 | |
| SCHEMBL20303983 | 0.94 | MAPK1 (0.54) | MAPK1MCL1KDM4EHSD17B10CYP1A2 | |
| SCHEMBL3171 | 0.94 | MAPK1 (0.54) | MAPK1MCL1KDM4EHSD17B10CYP1A2 | |
| SCHEMBL7305358 | 0.94 | MAPK1 (0.54) | MAPK1MCL1KDM4EHSD17B10CYP1A2 | |
| SCHEMBL6248372 | 0.92 | MAPK1 (0.53) | MAPK1MCL1KDM4EHSD17B10CYP1A2 | |
| SCHEMBL7199566 | 0.92 | MAPK1 (0.53) | MAPK1MCL1KDM4EHSD17B10CYP1A2 | |
| SCHEMBL1615850 | 0.92 | MAPK1 (0.53) | MAPK1MCL1KDM4EHSD17B10CYP1A2 | |
| SCHEMBL3767660 | 0.92 | MAPK1 (0.53) | MAPK1MCL1KDM4EHSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336868-A1 | COMPOSITIONS COMPRISING ADAMANTYL ESTER-CONTAINING COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2024-10-10 | — | — | US | disclosed |
| EP-4063358-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4051685-A1 | MACROCYCLIC COMPOUNDS | Zeno Management, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| EP-3558971-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-02-23 | — | — | EP | disclosed |
| WO-2021126316-A1 | MACROCYCLIC COMPOUNDS | ZENO MANAGEMENT, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-10829452-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3356345-A1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-20180186745-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-05 | — | — | US | disclosed |
| EP-2408766-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Schering Corporation (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010107765-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186745-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, EZH2 | MAPK1 3712/4885MCL1 126/4885KDM4E 55/4885 |
| US-10829452-B2 | Histone methyltransferase inhibitors | EHMT1, DOT1L, EHMT2 | MAPK1 2327/4885MCL1 114/4885KDM4E 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.